Effects of monoglucosyl hesperidin on human lymphatic circulatory function: A randomized placebo-controlled, double-blind, crossover trial.

While no effect was detected in the full cohort, in the subgroup analysis of participants with no exercise habit, monoglucosyl hesperidin intake significantly increased or showed a trend toward an increase in the thoracic duct diameter (Variation maximum value in the amount of change and the rate of change were p < 0.01 and p < 0.01, respectively; Variation minimum value in the amount of change and the rate of change were p = 0.06 and p < 0.01 respectively; ).

also in 53,322 other papers

The mean ± standard deviation for the minimum variation was 0.39 ± 0.86 mm (95% CI, − 0.33 mm to 1.11 mm) for the test tablet intake and 0.17 ± 0.18 mm (95% CI, 0.02 mm to 0.32 mm) for the control tablet intake, with a significant trend between two groups for the trial tablet ( p = 0.06), order ( p = 0.15), and phase factors ( p = 0.07).

also in 9,775 other papers